All In Biotech

Drug Trial Radar · NCT01727726

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator Controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Last checked: Nov 20, 2026Latest source record: Jun 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,182

Actual

Start

Dec 2012

Primary completion

Oct 17, 2016

Study completion Nov 10, 2016

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.

Conditions

  • Depressive Disorder
  • Depression
  • Depressive Disorder, Major
  • Mood Disorders
  • Mental Disorders

Interventions

  • BrexpiprazoleDrug

    tablet/capsule

  • Seroquel XRDrug

    tablet/capsule

  • PlaceboDrug

    tablet/capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Montgomery Asberg Depression Rating Scale (MADRS)Time frame: Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).

Locations

76 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Bellflower, California

  • Site not named

    Beverly Hills, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Glendale, California

  • Site not named

    Irvine, California

  • Site not named

    Redlands, California

  • Site not named

    San Diego, California

  • Site not named

    Upland, California

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville Beach, Florida

  • Site not named

    Leesburg, Florida

  • Site not named

    Melbourne, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Oakland Park, Florida

  • Site not named

    Orange City, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Decatur, Georgia

  • Site not named

    Lake Charles, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Belmont, Massachusetts

  • Site not named

    Roslindale, Massachusetts

  • Site not named

    Watertown, Massachusetts

  • Site not named

    Creve Coeur, Missouri

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Columbus, Ohio

  • Site not named

    Dayton, Ohio

  • Site not named

    Edmond, Oklahoma

  • Site not named

    Portland, Oregon

  • Site not named

    Salem, Oregon

  • Site not named

    Dallas, Texas

  • Site not named

    Murray, Utah

  • Site not named

    Herndon, Virginia

  • Site not named

    Richmond, Virginia

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.